Leerink Partnrs Forecasts Cencora’s Q1 Earnings (NYSE:COR)

Cencora, Inc. (NYSE:COR) – Stock analysts at Leerink Partnrs increased their Q1 2025 earnings per share (EPS) estimates for Cencora in a note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $3.45 per share for the quarter, up from their prior forecast of $3.43. The consensus estimate for Cencora’s current full-year earnings is $13.64 per share. Leerink Partnrs also issued estimates for Cencora’s Q2 2025 earnings at $4.12 EPS, Q3 2025 earnings at $3.73 EPS, Q4 2025 earnings at $3.70 EPS, FY2025 earnings at $14.99 EPS, FY2027 earnings at $18.91 EPS and FY2028 earnings at $20.72 EPS.

COR has been the subject of several other reports. JPMorgan Chase & Co. upped their price target on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Wells Fargo & Company raised their target price on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Barclays upped their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday. Leerink Partners dropped their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Finally, UBS Group lifted their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $271.20.

Cencora Stock Performance

Shares of Cencora stock opened at $247.76 on Friday. Cencora has a fifty-two week low of $191.11 and a fifty-two week high of $250.80. The company’s 50 day moving average price is $231.77 and its two-hundred day moving average price is $230.76. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The firm has a market capitalization of $48.82 billion, a P/E ratio of 32.99, a P/E/G ratio of 1.49 and a beta of 0.44.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $3.34 EPS for the quarter, beating the consensus estimate of $3.21 by $0.13. The business had revenue of $79.05 billion during the quarter, compared to the consensus estimate of $77.68 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%.

Institutional Investors Weigh In On Cencora

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD bought a new position in shares of Cencora in the first quarter valued at approximately $2,183,619,000. JPMorgan Chase & Co. purchased a new stake in Cencora in the first quarter worth $1,199,695,000. Boston Partners purchased a new stake in Cencora in the 1st quarter worth about $1,001,269,000. Capital Research Global Investors bought a new stake in shares of Cencora in the first quarter valued at approximately $650,424,000. Finally, Bessemer Group Inc. bought a new stake in shares of Cencora during the 1st quarter valued at $556,245,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.80% of the stock is currently owned by company insiders.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend is Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.